Colin Weekes, MD, PhD, associate professor, Department of Medicine and Medical Oncology, University of Colorado, on molecular phenotyping in pancreatic cancer patients.
Colin Weekes, MD, PhD, associate professor, Department of Medicine and Medical Oncology, University of Colorado, on molecular phenotyping in pancreatic cancer. Weekes says molecular phenotyping is already happening in cancers like lung cancer, and the benefit of phenotyping is that medical professionals can give proper treatments to patients by targeting those phenotypes. He adds that phenotyping changes the outcomes in small, unique patient populations, which in turn that information then aids in the treatment of patients overall.
Weekes says the difficulty in phenotyping for pancreatic cancer is the stroma component of the disease. He says the answer for phenotyping in that particular cancer comes down to better understanding the tumor microenvironment and its interaction with the patient’s genetic makeup.
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More